| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
ImmunoGen, Inc. (IMU.DE) is a clinical-stage biotechnology company pioneering antibody-drug conjugate (ADC) therapies to combat cancer. Headquartered in Waltham, Massachusetts, and listed on the Deutsche Börse (XETRA), ImmunoGen specializes in developing targeted ADCs that deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. The company's lead candidate, mirvetuximab soravtansine, is in Phase III trials for platinum-resistant ovarian cancer, while pivekimab sunirine targets CD123 in acute myeloid leukemia (Phase II). ImmunoGen's robust preclinical pipeline includes collaborations with industry giants like Roche, Novartis, and Eli Lilly, enhancing its R&D capabilities. Operating in the high-growth oncology sector, ImmunoGen leverages its ADC expertise to address unmet medical needs, positioning itself as a key player in next-generation cancer therapeutics. With a market cap of ~€1.14 billion (2022), the company balances innovation with strategic partnerships to drive long-term value.
ImmunoGen presents a high-risk, high-reward opportunity for investors focused on oncology innovation. The company’s ADC platform and late-stage pipeline (e.g., mirvetuximab for ovarian cancer) offer significant upside if trials succeed, but its €222.9 million net loss (2022) and negative operating cash flow (-€229.8 million) underscore reliance on clinical milestones and partnerships. A beta of 1.17 indicates higher volatility than the market, typical of biotech firms. Strengths include collaborations with pharma leaders (Roche, Novartis) and a niche focus on ADCs, but competition in targeted cancer therapies and cash burn (€275.1 million reserves) pose risks. Approval of mirvetuximab could be a near-term catalyst, though dilution or additional debt may be needed to fund operations.
ImmunoGen competes in the crowded ADC oncology space, differentiating itself through its proprietary linker-payload technology and folate receptor-alpha (FRα) targeting expertise. Its lead candidate, mirvetuximab, addresses platinum-resistant ovarian cancer—a niche with limited effective therapies—giving it first-mover potential. However, rivals like AstraZeneca (Enhertu) and Gilead (Trodelvy) have established ADC franchises with broader indications, leveraging larger commercial infrastructures. ImmunoGen’s partnerships (e.g., with MacroGenics for IMGC936) mitigate R&D costs but dilute control. The company’s focus on hematologic malignancies (e.g., pivekimab for AML) pits it against ADC leaders like Pfizer (Mylotarg) and emerging biotechs. While its pipeline depth is promising, ImmunoGen lacks commercial-scale manufacturing, relying on collaborators for production—a disadvantage versus vertically integrated peers. Its €152.4 million debt is manageable, but scalability post-approval remains a challenge without a big pharma acquirer.